UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or ...

Biotricity, Inc. (OTC:BTCY) Q3 2021 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Mark Forney - MKR IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Kyle Bauser - Colliers Securities Chris Jarrous - Dunlap Equity Jeff Porter - Porter Capital Management Liam Sherif - Platinum Point Capital Operator Good day and welcome to the Biotricity Fiscal Third Quarter 2021 Financial Results Conference Call. Today's conference is being recorded. At this ...

Biotricity, Inc. (OTC:BTCY) Q2 2021 Results Conference Call November 19, 2020 5:00 PM ET Company Participants Mark Forney - MKR Investor Relations Waqqas Al-Siddiq - CEO John Ayanoglou - CFO Conference Call Participants Kevin Dede - H.C. Wainwright Chris Jarrous - Dunlap Equity Operator Good day and welcome to the Biotricity's Fiscal Second Quarter 2021 Q2 Financial Results Conference Call. Today's conference is being recorded. And at this time, I would like to turn the conference over to Mark Forney, MKR I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------------------------------------------------|---------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant in its charter) Nevada 30-0983531 State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the period from ______________ to_______________ Commission file number: 333-201719 BIOTRICITY INC. (Exact name of registrant in its charter) Nevada 30-0983531 State or Other Jurisdic ...

Company Overview - The company is a healthcare technology firm focused on developing software and hardware solutions for managing chronic health issues, with its first product being a wearable medical cardiac solution [275]. Revenue Recognition - The company adopted ASC 606 for revenue recognition on April 1, 2018, which requires revenue to be recognized when promised goods or services are transferred to customers [276]. - The Bioflux mobile cardiac telemetry device can be worn for up to 30 days, with revenues generated from device sales and technology fees, which are recognized when performance obligations are satisfied [277]. Financial Performance - For the fiscal year ended March 31, 2019, the Company sold approximately 300 Bioflux MCT devices, generating total income of $398,200 from device sales and technology fees [308]. - The net loss for the fiscal year ended March 31, 2019, was $8,592,065, a slight decrease from the net loss of $8,623,738 in the previous fiscal year [314]. - Total operating expenses for the fiscal year ended March 31, 2019, increased to $8,741,601 from $7,723,734 in the fiscal year ended March 31, 2018 [309]. - General and administrative expenses rose by $1,497,682 to $7,458,855 for the fiscal year ended March 31, 2019, primarily due to costs associated with establishing a sales force and increasing payroll [310]. - Research and development expenses decreased to $1,282,746 for the fiscal year ended March 31, 2019, down from $1,762,561 in the previous year [311]. - The Company has an accumulated deficit of $35,039,495 as of March 31, 2019 [319]. Cash Flow and Financing - Cash used in operating activities for the fiscal year ended March 31, 2019, was $5,220,847, an increase from $4,874,535 in the previous fiscal year [326]. - Net cash provided by financing activities was $4,556,544 for the fiscal year ended March 31, 2019, compared to $5,289,281 in the prior year, primarily due to the issuance of common shares and promissory notes [327]. - During the year ended March 31, 2019, the Company raised net proceeds of $3,638,010 through the issuance of 2,635,353 common shares [322]. - The company has entered into an arrangement with a private equity firm to raise up to $25 million in additional capital, subject to certain conditions [324]. - The company anticipates needing to seek additional debt or equity capital to respond to business opportunities and challenges, including ongoing operating expenses and intellectual property protection [324]. - The company believes its existing cash and anticipated near-term equity financings will be sufficient for the next twelve months from the filing date of the Annual Report [324]. - Future financing terms may be dilutive to common stockholders, and there is no assurance that additional capital can be raised on acceptable terms [324]. Research and Development - The company continues to pursue the development of its next generation MCT product and other new products [317]. - The company plans to further develop Bioflux and Biolife products to increase market penetration and expand its intellectual property platform [324]. - The company expects to require approximately $4 million to grow its sales team and order devices for revenue generation, with an additional $7 million needed to accelerate commercialization of Bioflux and Biolife products [324]. Inventory and Taxation - The company records inventory at the lower of cost or net realizable value, with write-downs charged to cost of revenue for obsolete or excess inventory [279]. - The company accounts for income taxes in accordance with ASC 740, recognizing deferred tax assets and liabilities based on enacted tax rates expected to apply in future periods [292]. Other Financial Information - The company has not entered into derivative instruments to offset foreign currency fluctuations, and its Canadian subsidiary operates in Canadian dollars while the parent company operates in U.S. dollars [284]. - As of March 31, 2019, there were no potentially dilutive shares outstanding, indicating a basic and diluted earnings per share calculation without dilution [281]. - The company has no off-balance sheet arrangements that could affect its financial condition or results of operations [329]. - Cash and derivative liabilities are classified as Level 1 and Level 2 financial instruments, respectively, with the carrying value of certain financial instruments approximating their fair values due to their short-term nature [289]. - The company is currently evaluating the effects of FASB ASU 2018-07 on its consolidated financial statements, which expands the scope of stock compensation to include nonemployee transactions [298].